IpiNovyx Bio, Inc.

West Nyack, NY · Founded 2021 · CIK 0001887961 · Biotech · Private

Selective proteasome inhibitors for cancer, autoimmune, and inflammatory disease treatment

ipinovyx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$7.0M
1 Form D · Oct 2021
60 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$7,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2527Insilico Medicine, Inc.—$20M
2528Nuvectis Pharma, Inc.—$16M
2529ImmuneBridge Inc.—$16M
2530IpiNovyx Bio, Inc.—$7.0M
2531Lang Artificial Intelligence, Inc.—$11M
2532STEMLINE THERAPEUTICS INC—$2.6M
2533Form Bio—$16M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Marc AppelDirector · Executive Officer
  • Lutz GiebelDirector
  • James GrahamDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.